HoFH is a genetic disorder of lipid metabolism resulting in severely elevated LDL-C and early onset ASCVD and increased CV events and mortality. Individuals with HoFH are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors, and may benefit from treatment modalities with other mechanisms of action. This…